Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Orexo to acquire Biolipox
– building a specialty pharma company driven by innovation


Orexo AB (OMX Nordic List, Mid Cap: ORX) and the principal owners of Biolipox AB have reached an agreement under which Orexo will acquire Biolipox, an innovative Swedish research-based pharmaceutical company that develops new therapies for inflammatory diseases, including pain management and respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

The acquisition will create an innovative specialty pharma company with a broad product pipeline, global partnerships with major financial potential, and established sales channels. Substantial shareholder value will be created through operational synergies and by optimizing the potential of the combined product pipeline.

The transaction will take place through an issue in kind to Biolipox\'s shareholders. The deal values Biolipox at SEK 856[1] million, and payment will be made through an issue of a maximum of 8,560,000 Orexo shares. The final structure of the transaction is dependent on Orexo\'s completion of due diligence of Biolipox. The deal is also conditional upon approval of the issue in kind by an extraordinary general meeting of Orexo and customary regulatory approvals.

A press conference will be held jointly by Orexo and Biolipox at 10 a.m. today, Monday, 15 October 2007. Location: Summit, Grev Turegatan 30, Stockholm.

Håkan Åström, Chairman of the Board of Orexo, comments: 'The combination of Orexo and Biolipox will create a larger and more robust pharmaceutical company with a broad and attractive product pipeline. Orexo\'s business model, combined with the Biolipox innovative research pipeline is an exciting combination to create value.'

The transaction in brief
Orexo will acquire Biolipox through an issue in kind. With the settlement price used in the transaction (SEK 100 per share based on an average share price during the last 45 days of trading), the new Orexo will have an estimated market capitalization of approximately SEK 2.3 billion. The company will retain the Orexo name. Following the transaction, Biolipox\'s shareholders will own 38% of the combined company. Biolipox main owners are committed to a lock-up period of three months, following closing of the transaction.

Employees and management
The two companies have together approximately 120 employees, including nearly 90 engaged in drug development. The Orexo head office will remain in Uppsala, Sweden. Torbjörn Bjerke M.D., currently CEO of Biolipox, will serve as President and CEO of the new company. Claes Wenthzel will continue to serve as Executive Vice President and CFO, and Håkan Åström will continue as Chairman of the Board. Orexo\'s current CEO, Zsolt Lavotha, will be leaving his operational responsibilities in the company for personal reasons and will serve as Senior Advisor to Orexo\'s board.

Operations
Orexo will develop as a growing pharmaceutical company focusing on specialty pharmaceuticals. Primary focus will be on development and commercialization of products primarily in the areas of pain management and respiratory diseases targeting well defined patient groups and specialist physicians, enabling Orexo to play a fully integrated role from research to commercialization.

Biolipox\'s pipeline includes several development projects in the areas of pain management and respiratory diseases. The company\'s strategy has been to seek new partnerships at an early stage in an effort to reduce financial risk. The combined company\'s product pipeline will consist of a number of priority projects, most of which are in late stage development, as well as a number of other projects which will be evaluated by company management. Tangible synergies and efficiency gains can thereby be achieved.

'Orexo has since its listing in 2005 actively been working on identifying and evaluating a number of acquisition candidates. We see this deal as an important step forward in achieving a broader product pipeline that will bring us closer to our vision of crea


Publisher Contact Information:

Biolipox AB
+46-8-5248 3102
torbjorn.bjerke@biolipox.com

Company profile of Biolipox AB
Past press releases of Biolipox AB.

Data


27,746
Tech investments
From our Online Data Service
17,891
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.